https://www.selleckchem.com/pr....oducts/gsk2126458.ht
Metastatic Merkel cell carcinoma (mMCC) has traditionally been managed with palliative chemotherapy regimens or best supportive care (BSC). Avelumab, a novel anti-programmed death-ligand 1 (PD-L1) human monoclonal antibody for mMCC treatment, is being studied in the pivotal JAVELIN Merkel 200 trial. Incorporating trial results, this analysis aimed to evaluate the cost-utility of avelumab in Taiwan. A de novo partitioned-survival model with three key health states related to survival (progression-free disease, progressed disease, and
Like
Comment
Share
